Viridian Therapeutics to Participate in the Wedbush PacGrow Healthcare Virtual Conference

Rhea-AI Summary

Viridian Therapeutics (Nasdaq: VRDN) announced that Jonathan Violin, Ph.D., and Barrett Katz, M.D., will participate in a panel presentation at the Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021. The panel, titled TED Talk – State of Play in Thyroid Eye Disease, is scheduled for 1:45 p.m. ET. Webcast details can be found on the company’s website, and a replay will be available for 90 days after the live event. Viridian's lead program, VRDN-001, targets thyroid eye disease, an autoimmune condition affecting vision and causing significant patient discomfort.

BOULDER, Colo., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer, and Barrett Katz, M.D., M.B.A., Chief Medical Officer of Viridian, will participate in a panel presentation at the Wedbush PacGrow Healthcare Virtual Conference, which is scheduled to take place from August 10 – 11, 2021.

Event:	The Wedbush PacGrow Healthcare Virtual Conference
Panel:	TED Talk – State of Play in Thyroid Eye Disease (TED)
Date:	Wednesday, August 11th
Fireside Chat Time:	1:45 p.m. ET

Webcast information for this event will be accessible on the Events page under the Investors section of the Viridian Therapeutics website at www.viridiantherapeutics.com. A replay of this panel will be archived on the website and available for approximately 90 days following the live event.

About Viridian Therapeutics

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is an anti-IGF-1R monoclonal antibody in development for TED, a debilitating auto-immune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles, and eyelids. Viridian is based in Boulder, Colorado, and Waltham, Massachusetts. Learn more about Viridian and its programs at https://www.viridiantherapeutics.com/.

Follow us on Twitter @ViridianThera and on LinkedIn.

Viridian Contacts:
Investors:
Dan Ferry
LifeSci Advisors
617-430-7576
IR@viridiantherapeutics.com

Media:
Darby Pearson
Verge Scientific Communications
703-587-0831
PR@viridiantherapeutics.com

FAQ

What is the date of the Wedbush PacGrow Healthcare Virtual Conference for Viridian Therapeutics?

The conference will take place on August 10-11, 2021.

What time is Viridian Therapeutics' panel discussion at the conference?

The panel discussion is scheduled for 1:45 p.m. ET on August 11, 2021.

What is the topic of Viridian Therapeutics' panel presentation?

The presentation is titled 'TED Talk – State of Play in Thyroid Eye Disease'.

How can I access the webcast of Viridian Therapeutics' panel?

Webcast information will be available on the Events page of the Viridian Therapeutics website.

What is VRDN-001 and its significance for patients?

VRDN-001 is an anti-IGF-1R monoclonal antibody in development for thyroid eye disease, aiming to address a serious condition affecting vision.